Harmony Biosciences Holdings, Inc. $HRMY Stock Holdings Lowered by Vanguard Group Inc.

Vanguard Group Inc. reduced its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 5.6% during the fourth quarter, Holdings Channel reports. The firm owned 4,813,357 shares of the company’s stock after selling 283,819 shares during the period. Vanguard Group Inc. owned approximately 0.08% of Harmony Biosciences worth $180,116,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Robeco Institutional Asset Management B.V. raised its holdings in shares of Harmony Biosciences by 0.6% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 47,085 shares of the company’s stock worth $1,762,000 after purchasing an additional 298 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of Harmony Biosciences by 1.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 28,639 shares of the company’s stock worth $789,000 after purchasing an additional 348 shares in the last quarter. Nebula Research & Development LLC raised its holdings in shares of Harmony Biosciences by 2.0% in the 2nd quarter. Nebula Research & Development LLC now owns 17,403 shares of the company’s stock worth $550,000 after purchasing an additional 348 shares in the last quarter. Amalgamated Bank raised its holdings in shares of Harmony Biosciences by 3.8% during the third quarter. Amalgamated Bank now owns 11,328 shares of the company’s stock valued at $312,000 after acquiring an additional 417 shares during the period. Finally, Profund Advisors LLC raised its holdings in shares of Harmony Biosciences by 5.1% during the third quarter. Profund Advisors LLC now owns 10,803 shares of the company’s stock valued at $298,000 after acquiring an additional 520 shares during the period. 86.23% of the stock is currently owned by institutional investors.

Key Harmony Biosciences News

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: Harmony Biosciences reaffirmed 2026 net revenue guidance of over $1 billion and said demand for WAKIX remained strong, which helps support the long-term outlook. Business Wire article
• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and a $55 price target, citing positive discussions with senior management and reinforcing bullish sentiment on the stock. InsiderMonkey article
• Neutral Sentiment: Several articles noted Harmony Biosciences as a small-cap value name with a relatively low forward P/E, which may attract value investors but does not directly change the near-term earnings picture. InsiderMonkey article
• Neutral Sentiment: Truist raised its price target to $29 from $25 but kept a Hold rating, suggesting only limited upside from current levels. Tickerreport article
• Negative Sentiment: Q1 earnings of $0.55 per share missed estimates of $0.76, and revenue of $215.4 million also came in below expectations, which is the main reason shares are under pressure today. Zacks article
• Negative Sentiment: Management said Q1 market access headwinds were more pronounced this year, which may raise investor concerns about near-term execution even with strong year-over-year revenue growth. Business Wire article

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HRMY. Wall Street Zen lowered shares of Harmony Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. UBS Group lowered their price objective on shares of Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Needham & Company LLC lowered their price objective on shares of Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Zacks Research raised shares of Harmony Biosciences from a “strong sell” rating to a “hold” rating in a research report on Friday, May 1st. Finally, Weiss Ratings downgraded shares of Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $40.89.

Harmony Biosciences Stock Performance

Shares of HRMY opened at $30.99 on Monday. The company’s fifty day moving average is $29.01 and its 200-day moving average is $33.04. Harmony Biosciences Holdings, Inc. has a 12 month low of $25.52 and a 12 month high of $40.87. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of 12.50, a price-to-earnings-growth ratio of 0.43 and a beta of 0.97. The company has a quick ratio of 3.56, a current ratio of 3.58 and a debt-to-equity ratio of 0.15.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.21). Harmony Biosciences had a return on equity of 17.19% and a net margin of 16.20%.The business had revenue of $215.39 million for the quarter, compared to analyst estimates of $220.84 million. During the same quarter last year, the company earned $0.78 EPS. The business’s revenue for the quarter was up 16.6% compared to the same quarter last year. Equities analysts expect that Harmony Biosciences Holdings, Inc. will post 3.29 EPS for the current fiscal year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.